Apnimed (APMD) director’s options span 2033 and 2036
Rhea-AI Filing Summary
Apnimed, Inc. (APMD) reported the initial equity holdings of director Paul R. Fonteyne in an initial statement of beneficial ownership. The filing lists two stock option awards over Class A Common Stock with specified exercise prices, share amounts, vesting schedules, and expiration dates.
One option allows purchase of 51,890 shares at $4.0000 per share, expiring on September 18, 2033, vesting 25% after twelve months of continuous service from September 18, 2023, with the remainder vesting in substantially equal quarterly installments over 36 months. A second option covers 44,477 shares at $8.1500 per share, expiring on July 7, 2036, with 25% vesting after twelve months of continuous service from July 7, 2026 and the remainder vesting in substantially equal quarterly installments over 36 months.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
FONTEYNE PAUL R.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 96,367 shares (Direct)
Footnotes (2)
- F1. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F2. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Option underlying shares (grant 1): 51,890 shares
Exercise price (grant 1): $4.0000 per share
Expiration date (grant 1): 2033-09-18
+5 more
8 metrics
Option underlying shares (grant 1)
51,890 shares
Underlying Class A Common Stock for stock option at $4.0000 exercise price expiring September 18, 2033
Exercise price (grant 1)
$4.0000 per share
Stock Option (Right to Buy) over 51,890 underlying Class A Common Stock shares
Expiration date (grant 1)
2033-09-18
Expiration of first stock option reported for Paul R. Fonteyne
Option underlying shares (grant 2)
44,477 shares
Underlying Class A Common Stock for stock option at $8.1500 exercise price expiring July 7, 2036
Exercise price (grant 2)
$8.1500 per share
Second Stock Option (Right to Buy) over 44,477 underlying Class A Common Stock shares
Expiration date (grant 2)
2036-07-07
Expiration of second stock option reported for Paul R. Fonteyne
Initial vesting portion
25%
Portion of shares vesting after twelve months of continuous service for each option grant
Remaining vesting period
36 months
Period over which remaining option shares vest in substantially equal quarterly installments
Key Terms
Stock Option (Right to Buy), Class A Common Stock, vest and become exercisable, continuous service
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
vest and become exercisable financial
"shares subject to such option vest and become exercisable when the Reporting Person"
continuous service financial
"twelve months of continuous service after September 18, 2023"
FAQ
What does Apnimed, Inc. (APMD) disclose in Paul R. Fonteyne’s Form 3?
Apnimed discloses director Paul R. Fonteyne’s initial beneficial ownership, consisting of two stock option awards on Class A Common Stock, detailing the share amounts, exercise prices, vesting schedules, and expiration dates, without reporting any purchase or sale transactions in this filing.
What are the exercise prices of Paul R. Fonteyne’s Apnimed (APMD) stock options?
One option has an exercise price of $4.0000 per share and the other has an exercise price of $8.1500 per share, each relating to stock options on Apnimed’s Class A Common Stock as reported in the Form 3 filing.
When do Paul R. Fonteyne’s Apnimed (APMD) stock options expire?
The $4.0000 stock option expires on September 18, 2033, while the $8.1500 stock option expires on July 7, 2036. These expiration dates define the latest dates by which the respective options can be exercised, subject to vesting and continued service conditions.
How do the Apnimed (APMD) stock options granted to Paul R. Fonteyne vest?
Each option vests 25% after twelve months of continuous service from its respective start date, with the remaining 75% vesting in substantially equal quarterly installments over the following 36 months, conditioned on Mr. Fonteyne’s continuous service to Apnimed on each vesting date.
Does Paul R. Fonteyne’s Form 3 for Apnimed (APMD) show any stock purchases or sales?
No stock purchases or sales are reported. The Form 3 lists only stock option holdings and their terms for Paul R. Fonteyne, without any acquired or disposed share transactions indicated in the structured transaction data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
